Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 27:16:497-516.
doi: 10.2147/BCTT.S482504. eCollection 2024.

Recent Advances in Immunotherapy for Breast Cancer: A Review

Qian-Er Wen  1 , Liang Li  1 , Rui-Qi Feng  1 , De-Hui Li  2 , Chang Qiao  1 , Xiao-Song Xu  3 , Yan-Jing Zhang  2
Affiliations
Review

Recent Advances in Immunotherapy for Breast Cancer: A Review

Qian-Er Wen et al. Breast Cancer (Dove Med Press). .

Abstract

Breast cancer is one of the most common malignant tumors in women in the world, and its incidence is increasing year by year, which seriously threatens the physical and mental health of women. Triple negative breast cancer (TNBC) is a special molecular type of breast cancer in which estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 are negative. Compared with other molecular types of breast cancer, triple-negative breast cancer (TNBC) has high aggressiveness and metastasis, high recurrence rate, lack of effective therapeutic targets, and usually poor clinical treatment effect. Chemotherapy was the main therapeutic means used in the past. With the advent of the immune era, immunotherapy has made a lot of progress in the treatment of triple-negative breast cancer (TNBC), bringing new therapeutic hope for the treatment of triple-negative breast cancer. This review combines the results of cutting-edge medical research, mainly summarizes the research progress of immunotherapy, and summarizes the main treatment methods of triple-negative breast cancer (TNBC) immunotherapy, including immune checkpoint inhibitors, tumor vaccines, adoptive immunotherapy and the application of traditional Chinese and western medicine. It provides a new idea for the treatment of triple negative breast cancer (TNBC).

Keywords: adoptive immunotherapy; breast cancer; immune checkpoint inhibitors; immunotherapy; triple negative breast cancer; tumor vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Tumor immune microenvironment By Figdraw (ID:TYWYUdd4bd).
Figure 2
Figure 2
Mechanism of immune checkpoint inhibitors. By Figdraw (ID: OARPWbd2bb).
Figure 3
Figure 3
Chinese medicine’s treatment of triple-negative breast cancer By Figdraw (ID: OWOWO99988).
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca a Cancer J Clini. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Li Z, Qiu Y, Lu W, et al. Immunotherapeutic interventions of Triple Negative Breast Cancer. J Transl Med. 2018;16(1):147. doi:10.1186/s12967-018-1514-7 - DOI - PMC - PubMed
    1. Wang X, Qi Y, Kong X, et al. Immunological therapy: a novel thriving area for triple-negative breast cancer treatment. Cancer Lett. 2019;442:409–428. doi:10.1016/j.canlet.2018.10.042 - DOI - PubMed
    1. Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2021;70(3):607–617. doi:10.1007/s00262-020-02736-z - DOI - PMC - PubMed
    1. Mo S, Yang JN, Dong C. Interpretation of the IMpassion130 study: alemtuzumab plus albumin-bound paclitaxel in the treatment of advanced triple-negative breast cancer in a Phase III clinical trial. Chine j Canc. 2019;29(4):313–320.